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lations (p < 0.05) were found between the MSLQ measurement
and the number of hours college students spent with friends,
studying, class missed, as well as the number of extra-curricular
activities and alcohol consumed. The SAS-SR measurement, on
the other hand, were signiﬁcantly correlated (p < 0.05) with only
the number of hours college students spent with friends and class
missed. CONCLUSION: The MSLQ is a better indicator of
student productivity in college than the SAS-SR. This is because
the SAS-SR, which was originally developed to evaluate
employee productivity, measures functional items that may be
too sensitive for student-related activities. The MSLQ was
designed to measure students’ study strategies.
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OBJECTIVES: This analysis was conducted as part of a feder-
ally funded national pilot to evaluate electronic prescribing in
the community practice setting. The objective was to measure
the incidence and nature of prescribing errors on e-prescriptions
that required active intervention by dispensing pharmacists to
correct. METHODS: A panel of participating pharmacists
reported their Medication Therapy Interventions (MTI) using a
standardized documentation protocol. RESULTS: Data were
reported from 68 participating chain pharmacies in 5 states
during 312 work shifts between July and September, 2006.
During the study pharmacists reviewed 2,690 e-prescription
orders (new = 83.0%, reﬁll = 17.0%) and intervened 102 times
for an intervention rate of 3.8%. The rate at which pharmacists
identiﬁed problems on new e-Rxs was found to be nearly twice
that of reﬁlls (4.1% and 2.2%, respectively). The most common
reason for pharmacists’ interventions on e-prescriptions was to
supplement omitted information (31.9%), especially missing
directions. Dosing errors were also quite common (17.7%). The
most common response by pharmacists to e-Rx problems was to
contact the prescriber (64.1%), consult the patient’s proﬁle or
medication history (12.8%), and/or interview the patient or the
patient’s representative (9.4%). In most cases (56%), the e-Rx
order was changed and the prescription was ultimately dis-
pensed. In 15% of cases the e-Rx order was dispensed as written
following clariﬁcation by the prescriber. In 10% of cases the pre-
scription was not dispensed. An additional 12% of prescription
issues remained unresolved. Pharmacists required an average of
6.07 minutes to conduct their interventions on problematic e-
prescription orders, representing an incremental dispensing cost
of $4.74. CONCLUSION: Electronic prescribing has the poten-
tial to improve the safety and efﬁciency of patient care. However,
as currently implemented in the community practice setting, it
maintains selected threats to both. Best practice recommenda-
tions are offered to improve the implementation of this impor-
tant technology.
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OBJECTIVES: Drug-drug interactions (DDIs) are preventable
medical errors, yet exposure to DDIs continues despite systems
designed to prevent such exposures. The purpose of this study
was to examine pharmacy characteristics that may be associated
with dispensed potential DDIs. METHODS: This study com-
bined survey data from community pharmacies in 18 metropol-
itan statistical areas with pharmacy claims submitted to 4
pharmacy beneﬁt managers (PBM) over a 3 month period from
January 1 to March 31, 2003. Pharmacy characteristics of inter-
est included prescription volume, the number of full-time equiv-
alent pharmacist and pharmacy staff, computer software
programs and the ability to modify those programs with respect
to DDI alerts, the use of technologies to assist in receiving, ﬁlling
and dispensing medication orders, and prescription volume. The
dependent variable in this study was the rate of dispensed med-
ications that may interact. RESULTS: A total of 672 pharmacies
were included in the analysis. On average (+/−SD), the respon-
dents ﬁlled 1375+/−691 prescriptions per week, submitted
17,948+/−23,889 pharmacy claims to the participating PBMs,
had 1.2+/−0.3 full-time equivalent (FTE) pharmacists per hour
open, and 545 (81%) were afﬁliated with a chain drug store
organization. Factors signiﬁcantly related to an increased risk of
dispensing a potential DDI included pharmacist workload (OR
1.03, 95% CI 1.028 to 1.048), pharmacy stafﬁng (OR 1.10,
95% CI: 1.09 to 1.11), and various technologies (e.g., sophisti-
cated telephone systems, internet receipt of orders and reﬁll
requests) that assist with order processing as well as the ability
to modify DDI alert screening sensitivity and detailed pharma-
cological information about DDIs. CONCLUSION: This study
found there was an increase in the risk of dispensing a potential
DDIs and higher pharmacist and pharmacy workload, and use
of dispensing automation systems.
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OBJECTIVES: To quantify and characterize economic-content
in pharmaceutical advertisements in leading medical journals
from 1990–2003, and to determine if economic ads declined 
in journals after enactment of Section 114 of the 1997 Food 
and Drug Administration Modernization Act (FDAMA).
METHODS: Two researchers reviewed all pharmaceutical
advertisements in three leading general medical (New England
Journal of Medicine, JAMA, and Annals of Internal Medicine)
and three specialty journals (Circulation, Gastroenterology, Neu-
rology) in three speciﬁed months each year for 2000 through
2003. Using a standardized data collection form, we investigated
economic claims (e.g., ads using the words “value”, “price”,
“savings”, “hospitalization”), as well as presence of supporting
evidence. This work builds upon our previous research of eco-
nomic claims from 1990–1999, using an identical methodology.
We hypothesized that economic promotion in journals declined
after 1997 FDAMA Section 114, because that law encouraged
such promotion in direct-to-managed care communications and
signaled the FDA’s growing vigilance over the area. RESULTS:
We reviewed 2144 pharmaceutical ads from 1990–1999 and 
779 from 2000–2003. Economic content occurred in 11.1% of
ads in the 1990s, and 7.6% of ads in 2000–2003 (p = 0.0058).
The frequency of economic ads peaked in 1997 at 16.2% and
declined thereafter (test for trend: p = 0.0017), reaching a low
of 6.3% in 2002. The presence of any supporting evidence for
economic claims was similar in the 1990s and early 2000s
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(63.7% vs. 57.6%, p = 0.39). The most common type of eco-
nomic claim was that a product was “less expensive/costs less”
(50.6% in the 1990s vs. 32.2% from 2000–2003). CONCLU-
SION: The frequency of economic-content advertising in medical
journals has declined somewhat in recent years, possibly spurred
by Section 114 of FDAMA. Other factors, such as growth in
communication of health economic information through dossier
submissions to formulary committees in response to unsolicited
requests, may have also played a role.
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OBJECTIVES: To examine the impact of stock market crashes
on domestically-listed pharmaceutical company security prices.
METHODS: An event study methodology was employed to
assess the monthly abnormal returns of ﬁrms with historical
standard industrial classiﬁcations of 2834 (pharmaceutical
preparations) during major stock market crashes from 1929 to
2006. Financial returns were modeled via a single index market
model and the Patell standardized residual test was used to assess
statistical signiﬁcance. An estimation period was deﬁned as (−45,
−6) months and various event windows between months (−5, +5)
were tested relative to the event month of the market crash.
Aggregate results were presented as cumulative average abnor-
mal returns (CAAR). RESULTS: Overall, 10 market crashes were
identiﬁed between 1929 and 2006 wherein marketwide value
decreases equaled or exceeded 20%. Within the pharmaceutical
sector during the (−5, +5) event window, 5 crashes were associ-
ated with signiﬁcantly lower returns than the overall market
(1929, 1962, 1970, 1973, 1987) [CAAR = −18.31%, p < 0.05],
4 were associated with statistically similar returns (1937, 1940,
1946, 2000) [CAAR = −6.80%, p = NS], and 1 noted statisti-
cally higher returns (1990) [CAAR = +3.98%, p < 0.05]. CON-
CLUSION: This econometric analysis of the ﬁnancial markets
indicates that the pharmaceutical sector has historically per-
formed equal to or below the overall market in the months sur-
rounding and including stock market crashes. The implications
of this research suggest that security market assets of drug com-
panies do not offer improved performance during these times of
market instability.
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OBJECTIVES: In India, prescriptions are kept by the patient and
not with the pharmacist; and antibiotics may be obtained with
or without a prescription. Therefore, determining antibiotic use
is problematic, since there are no prescription records. The objec-
tive of this study was to develop a surrogate measure for antibi-
otic use in the community in India. METHODS: Surveillance of
antibiotic use was conducted in different residential areas that fall
under 5 municipal wards of New Delhi, India during December
2003–December 2004. Thirty retail pharmacies were enrolled for
the study and consumption of antibiotic use (bulk purchase data)
was collected by recording the quantities of all antibiotics pur-
chased by these pharmacies every month over one year. “Exit
interviews” were conducted with patients leaving the enrolled
pharmacies. 15–25 exit interviews were conducted for each phar-
macy per month over one year. Consumption of antibiotics was
deﬁned as total number of Deﬁned Daily Dose (DDD)/1000 pop-
ulation and DDD/1000 patients. The denominator for bulk data
was population of the ward and for exit interviews, number of
patients who visited the pharmacy. RESULTS: Bulk purchase data
and exit interview data showed a similar pattern of antibiotic use.
Consumption of antibiotics belonging to the ﬂuoroquinilone
group was much higher than others. Penicillins, cephalosporins
and macrolides showed almost equal usage in the community.
Exit interviews revealed that 22% of persons who visited the phar-
macies bought antibiotics. DDD/1000 patients for ﬂuro-
quinolone, penicillins, cephalosporins and macrolides were
34,493, 15,029, 13,270, and 11,800 respectively. Newer drugs
were used more than older drugs. CONCLUSION: Both drug use
methods are good indicators of antibiotic use in the community.
In future, we will use the exit interviews, since this method is less
dependent on commitment of the pharmacists as well as being a
means to collect additional information on patient perceptions
and prescriber behavior.
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OBJECTIVES: Antihypertensive therapy had been well estab-
lished to reduce hypertension-related morbidities and mortali-
ties, but the therapy option was still controversial. The aim of
this study was to determine whether different anti-hypertensive
agents have different risks of developing stroke in patients of
uncomplicated hypertension. METHODS: We conducted a ret-
rospective cohort study using Taiwan’s National Health Insur-
ance Reimbursement Database between January 1997 and
December 2004. A total of 11,017 patients 30 years old or older,
who were diagnosed as essential hypertension and were initiated
with different classes or combinations of antihypertensive drugs,
that are diuretics, beta-blockers, calcium channel blockers
(CCBs), angiotensin-converting-enzyme (ACE) inhibitors or
angiotensin-II receptor blockers (ARBs) and others, were identi-
ﬁed between January 1999 and December 2004. In these patients
we excluded those who had had other related comorbidities (dia-
betes, ischemic heart diseases and other heart diseases, cere-
brovascular diseases, and renal disorders) before initiation of
antihypertensive treatment. Therefore, 4285 newly diagnosed
uncomplicated hypertensive patients who received antihyperten-
sive therapies were remained for our analysis. We used the time-
dependent proportional hazards regression to analyze the
relative risk of developing ﬁrst-ever stroke among these patients.
RESULTS: There were 148 ﬁrst-ever stroke cases identiﬁed out
of these 4285 uncomplicated hypertensive patients. The hazard
ratio was higher for older patients, for male patients and in those
with poor medical compliance. The hazard ratios were 1.68 for
beta-blockers alone, 2.17 for other classes of antihypertensive
drugs and 4.00 (95% CI, 1.63–9.84) for combination of beta-
blockers and diuretics. Other signiﬁcant risk factors were hospi-
talization in prior months and coexistent use of anti-platelet
agents. CONCLUSION: There were higher hazard ratios of
stroke for certain antihypertensive drugs, alone or combined.
